In addition, other combinatorial approaches using MEKi such as the addition of panRAF inhibitors [54,55,56], ERK inhibitors [57], BET inhibitors [58], or PI3K inhibitors [59] could be a step forward for having an effective therapeutic weapon in the fight against aggressive NRAS-mutated melanomas. The gene discussed is NRAS; the disease is melanoma.